Relief Therapeutics Holding AG (RLFTF)

[tcm55]

News Rule with these guys and all stocks.IMO.
Drugs with significant positive Data will be in demand. Period.
Biggies must still be looking to find even a partial solution or treatments as part of a more successful short and long term answer to issues caused by COVID.
World wide cases still grow, even before the 'winter' flu season and expected 2nd waves.
Brazil, India, US etc

News Rules, Good or Bad, IMO...

Not good news for Roche.

"Meanwhile, the difference in time to hospital discharge or difference in time to improvement in ordinal clinical status to day 28 was not significant between the study drug and placebo groups.

Roche added that time to clinical failure to day 28 was longer in the Actemra arm compared with the placebo group, but was not statistically significant.

Furthermore, no statistical difference was observed in mortality between the study drug and placebo arms by day 28."

Worse news for Kodak.

NEW YORK, NY / ACCESSWIRE / September 25, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Eastman Kodak Company (NYSE:KODK)

CONTACT JAKUBOWITZ ABOUT KODK:
https://claimyourloss.com/securities/eastman-kodak-company-loss-submission-form/?id=9617&from=1

Class Period : July 27, 2020 - August 11, 2020

Lead Plaintiff Deadline : October 13, 2020

According to a filed complaint, defendants failed to disclose that the Company had granted its Executive Chairman, James Continenza, and several other Company insiders millions of dollars' worth of stock options immediately prior to the Company publicly disclosing that it had received the $765 million loan, which Defendants knew would cause Kodak's stock to immediately increase in value once the deal was announced. In addition, while in possession of this material non-public information, Continenza and other Company insiders purchased tens of thousands of the Company's shares immediately prior to the announcement, again at prices that they knew would increase exponentially once news of the loan became public.